FY2025 EPS Estimates for Amgen Raised by Cantor Fitzgerald

Amgen Inc. (NASDAQ:AMGN - Free Report) - Investment analysts at Cantor Fitzgerald raised their FY2025 earnings per share estimates for shares of Amgen in a research report issued to clients and investors on Friday, May 2nd. Cantor Fitzgerald analyst C. Gould now anticipates that the medical research company will post earnings per share of $20.85 for the year, up from their previous forecast of $20.50. Cantor Fitzgerald currently has a "Neutral" rating and a $305.00 target price on the stock. The consensus estimate for Amgen's current full-year earnings is $20.62 per share.

Other analysts have also recently issued research reports about the stock. Bank of America upped their price objective on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research report on Wednesday, March 5th. Johnson Rice set a $294.00 price target on Amgen in a report on Wednesday, March 5th. StockNews.com upgraded Amgen from a "buy" rating to a "strong-buy" rating in a report on Friday, May 2nd. UBS Group reissued a "neutral" rating and set a $315.00 target price (down from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Finally, Royal Bank of Canada cut their price target on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $310.23.

Amgen Trading Down 0.7 %

AMGN traded down $1.98 during mid-day trading on Monday, hitting $270.07. The stock had a trading volume of 611,604 shares, compared to its average volume of 2,756,070. The stock's fifty day simple moving average is $297.00 and its 200-day simple moving average is $290.23. The firm has a market capitalization of $145.20 billion, a price-to-earnings ratio of 35.77, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. Amgen has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned $3.96 EPS.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.53%. Amgen's payout ratio is 86.86%.

Insider Activity at Amgen

In other Amgen news, EVP Murdo Gordon sold 8,771 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total value of $2,585,603.09. Following the sale, the executive vice president now owns 44,186 shares in the company, valued at $13,025,590.94. This represents a 16.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP David M. Reese sold 8,711 shares of Amgen stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total value of $2,554,239.42. Following the transaction, the executive vice president now owns 62,147 shares of the company's stock, valued at $18,222,743.34. This represents a 12.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,707 shares of company stock worth $12,819,342. Insiders own 0.69% of the company's stock.

Institutional Trading of Amgen

Hedge funds have recently modified their holdings of the stock. Talbot Financial LLC increased its stake in shares of Amgen by 5.6% during the fourth quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company's stock worth $11,153,000 after purchasing an additional 2,274 shares during the period. Ascent Wealth Partners LLC lifted its holdings in shares of Amgen by 0.7% during the fourth quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock worth $2,352,000 after buying an additional 64 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Amgen by 6.0% in the third quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company's stock valued at $204,659,000 after acquiring an additional 35,785 shares during the period. ICICI Prudential Asset Management Co Ltd grew its stake in shares of Amgen by 242.2% in the fourth quarter. ICICI Prudential Asset Management Co Ltd now owns 23,999 shares of the medical research company's stock valued at $6,255,000 after acquiring an additional 16,985 shares in the last quarter. Finally, PFW Advisors LLC bought a new position in Amgen during the fourth quarter worth about $1,105,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.